Thrombotic Microangiopathies Clinical Trial
— m-TMAOfficial title:
Retrospective Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab: Clinical Characteristics and and Outcome of These Patients
NCT number | NCT06098378 |
Other study ID # | 8957 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 7, 2023 |
Est. completion date | June 7, 2025 |
Thrombotic microangiopathies (TMA) are defined as a triad combining mechanical hemolytic anemia, peripheral thrombocytopenia and ischemic organ damage. Mitomycin C is an alkylating agent used as chemotherapy in adenocarcinomas of the breast, lung, pancreas, rectum and anal carcinoma. Mitomycin-C-induced TMA (m-TMA) is a potentially serious complication of chemotherapy: its estimated incidence ranges from 4 to 15% and its mortality exceeds 70%, with an estimated median survival of 2 months. This can also be responsible for kidney failure, sometimes requiring hemodialysis. The time to onset of m-TMA varies from one week to 15 months after the last infusion and is believed to depend on the cumulative dose of mitomycin C. Eculizumab is a monoclonal antibody that binds to complement protein C5, blocking activation of the terminal complement pathway and formation of the membrane attack complex. This therapy has significantly changed the prognosis of patients with atypical hemolytic uremic syndrome (HUS), a disease in which complement activation plays a central role in TMA. Recently, a retrospective study suggested efficacy of eculizumab in TMA induced by gemcitabine, another chemotherapy, with normalization of platelets and LDH in 83% of patients, and partial or complete renal recovery in 67% and 17% of patients. These results provided arguments in favor of a potential benefit of complement-targeted therapies in TMA induced by certain chemotherapies. However, data on eculizumab in m-TMA remain extremely limited to date. The objective of this study is to describe the clinical, biological and histological presentation of patients with m-TMA and their evolution after treatment with or without eculizumab.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | June 7, 2025 |
Est. primary completion date | June 2025 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult patients (>=18 years) - Having received treatment with mitomycin C (regardless of the method of administration and indication) between 01/01/1990 and 12/31/2023 - and having developed a picture of thrombotic microangiopathy attributed to mitomycin C: - biological: defined as: thrombocytopenia <150G/L and mechanical hemolytic anemia (at least 3 out of 4 criteria: hemoglobin < 12g/dL, presence of schistocytes in blood smear, LDH > 1N, collapsed haptoglobin (< lower limit of the limit of laboratory normal) - or renal: pathological diagnosis of thrombotic microangiopathy on renal biopsy - having received or not treatment for the episode of microangiopathy, including or not complement inhibitors (Eculizumab). - Subject not opposing, after information, the reuse of their data for the purposes of this research Exclusion Criteria: - Subject having expressed opposition to participating in the study - Test for positive Shiga toxin - ADAMST13 activity <10% - Thrombotic microangiopathy attributed to metastatic cancer (infiltration of bone marrow or circulating erythroblasts) - Impossibility of providing the subject with informed information (difficulties in understanding the subject, etc.) - Subject under judicial protection - Subject under guardianship or curatorship |
Country | Name | City | State |
---|---|---|---|
France | Service de Néphrologie, Dialyse et Transplantation - CHU de Strasbourg - France | Strasbourg |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Strasbourg, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall and renal survival after the m-TMA episode | Files analysed retrospectively from January 01, 1990 to December 31, 2023 will be examined |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04098445 -
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
|
||
Recruiting |
NCT03605511 -
TTP and aHUS in Complicated Pregnancies
|
||
Not yet recruiting |
NCT05996679 -
Automated Surveillance, Alert, and Rapid Diagnosis of Thrombotic Microangiopathies: the ASARD-TMA Study
|
||
Completed |
NCT02222545 -
Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
|
Phase 2 | |
Recruiting |
NCT06102694 -
Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy
|
||
Completed |
NCT03252925 -
A Safety and Efficacy Study of NAC in Patients With TA-TMA
|
Phase 3 | |
Recruiting |
NCT05855083 -
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
|
Phase 2 | |
Completed |
NCT03384693 -
Defibrotide TMA Prophylaxis Pilot Trial
|
Phase 2 | |
Not yet recruiting |
NCT05702996 -
Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies
|
Phase 3 | |
Not yet recruiting |
NCT02373267 -
Screening of TMA Patients für ADAMTS13 Activity (Adamscreen)
|
N/A | |
Completed |
NCT02134171 -
Early Predictive Factors of Cardiac and Cerebral Involvement in TMA
|
N/A | |
Not yet recruiting |
NCT06182410 -
Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma
|
Phase 2 | |
Withdrawn |
NCT04970004 -
Study in Adult and Pediatric Patients With HSCT-TMA
|
||
Recruiting |
NCT03205995 -
Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
|
Phase 3 | |
Recruiting |
NCT04784455 -
Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy
|
Phase 3 | |
Active, not recruiting |
NCT04570397 -
Ravulizumab and COVID-19
|
Phase 3 | |
Recruiting |
NCT05634928 -
Construction of a Database for TMA
|
||
Completed |
NCT03518203 -
Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients
|
Phase 2 | |
Recruiting |
NCT04745195 -
Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium
|
||
Recruiting |
NCT06291415 -
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
|
Phase 1 |